Eutropics was founded in 2005 to apply a fundamental principle of cell biology to the discovery and development of clinical tools that aid in the diagnosis and treatment of cancer. Our methods provide important insight into an individual patient’s cancer that enables the practical exercise of personalized medicine. We have been applying this insight to develop clinically useful in vitro diagnostic assays that enable the identification of individually-tailored therapies to patients.
Eutropics’ CLIA-validated PraediCare Dx™ platform provides a biomarker technology for accelerating drug discovery and development. By aiding in the selection of patients who are likely to respond to treatments being tested the platform can help to bring more effective drugs to the clinic at greater speed and at reduced cost.
Predictive Biomarker Discovery
Biomarker-driven IVD (in vitro diagnostic) development:
PraediCare Dx™ is a first-in-class CLIA-validated LDT (laboratory diagnostic test) that predicts patients’ response to a wide range of apoptosis-inducing therapies. PraediCare Dx™ interrogates responsiveness of patient tumor cells from liquid biopsies (fresh or viably frozen peripheral blood or bone marrow samples) or cell lines to various drugs. Our BH3 profiling platform provides a functional readout for hematological malignancies including but not limited to: AML (acute myeloid leukemia), CLL (chronic lymphocytic leukemia), and MM (multiple myeloma). The readout combined with our proprietary analysis algorithm provides a powerful surrogate biomarker that correlates with patient response to treatment. Our statistical algorithm is specifically tailored for each biomarker discovery process.
Assay Development – Companion Diagnostic (CDx)
Our CLIA-certified laboratory is equipped with 510(k)-cleared flow cytometers and fluorescence-based plate readers. We provide assay development and regulatory expertise to develop CDx (companion diagnostic) using these platforms.
Assay Development – IVD/LDT
Our CLIA-certified laboratory is equipped with 510(k)-cleared flow cytometers and fluorescence-based plate readers. We provide assay development and regulatory expertise to develop an IVD (in vitro diagnostic) or an LDT (laboratory diagnostic test).
The Human Anti-Mouse Antibody (HAMA) IgG ELISA detection system is a direct enzyme-linked immunosorbent assay for the detection and semi-quantitation of human antibodies to mouse IgG (HAMA). The presence of human anti-mouse antibody (HAMA) has been associated with patients receiving injections of murine monoclonal antibody for diagnostic and/or therapeutic purposes. We provide this test in our CLIA-certified laboratory for detecting HAMA in patient serum samples.
Antibody/Antigen Detection Based Testing Services
Eutropics Pharmaceuticals has not received any reviews.
Eutropics Pharmaceuticals has not received any endorsements.